DXC Technology Unveils DXC Bionix™ to Provide Automated IT Services at Scale
DXC Technology (NYSE: DXC), the world’s leading independent, end-to-end IT services company, today unveiled DXC Bionix™, a new digital-generation services delivery model that promises to provide a comprehensive approach to intelligent automation at the scale required by the world’s top companies.
DXC Bionix leverages analytics and AI, lean processes and leading automation capabilities to produce greater insight, speed and efficiency across the company’s global delivery ecosystem. DXC is leveraging DXC Bionix to respond to client demand for greater IT performance and the need to digitally transform traditional IT environments and processes.
For DXC’s global delivery operations, the performance gains from DXC Bionix have been impressive:
- 50 percent to 80 percent reduction in time spent on operations;
- 25 percent reduction in testing costs; 50 percent defect reduction; 60 percent reduction in testing time;
- reduction in average applications deployment time from 180 minutes to 15 minutes;
- a 65 percent reduction in business process transaction time with assisted Robotic Process Automation (RPA);
- 71 percent of incidents auto-resolved or auto-diagnosed without human intervention; and
- an 82 percent elimination of issues through rules-based filtering and alert correlation.
“Technology innovation and intelligent automation are rapidly changing the IT services business, and clients want to maximize performance and business outcomes from technology investments,” said Stephen Hilton, executive vice president, Global Delivery, DXC Technology. “By bringing smart industrial engineering into our delivery processes, we can work in a highly dynamic, repeatable and scalable way to deliver exceptional and transformative solutions to our clients.”
DXC Bionix uses real-time data collection and analysis to continuously measure and elevate performance. This helps the company, and ultimately its clients, make more informed decisions, eliminate waste, and produce more predictable results.
“We are also empowering our workforce by investing in our people, driving a cultural shift and elevating skillsets to ensure that DXC has the right digital-generation talent to optimally meet current and future clients’ needs,” Hilton noted. “For DXC, our partners and clients, DXC Bionix enables us to work smarter, faster and more efficiently—achieving new thresholds of quality and performance.”
Combining Analytics and AI, Lean Processes, and Intelligent Automation
DXC Bionix provides a complete, high-definition view of the IT services delivery operating environment to yield deeper learning and more useful information. The result is fewer business disruptions, reduced human error and operational risks and lower costs. And because it enables Straight Through Processing, DXC Bionix becomes a smart, fast, performance-driven and secure delivery engine that increases performance and agility across the enterprise.
There are three core elements of DXC Bionix:
- Analytics and AI to gain new, real-time insights into the business and operations including data mining, machine learning and predictive intelligence to identify and proactively address opportunities for reducing costs and delivering innovation;
- Lean processes to eliminate inefficiencies and continually improve solutions delivery, and optimize work flows and team performance for better quality, consistency and outcomes; and
- Leading Automation capabilities, leveraging best-of-breed technologies from the DXC partner network combined with DXC innovation, to automate tasks, processes and workflows and to improve response time, accuracy and standardization.
“The next decade will see the mass adoption of artificial intelligence, machine learning and robotics within IT services which will reduce the unit cost of implementation,” Hilton added. “However, it will bring complexity.
“The competitive advantage of innovation will only be realized by companies that can simplify and manage this dynamic end-to-end at massive scale and as-a-service. DXC Bionix and its underlying platforms are how DXC will be at the forefront of this change, providing a competitive advantage for the company, our clients and partners.”
“A 70 percent reduction in backend incidents through predictive analytics is, from my stand point, amazing,” said Damian Bunyan, CIO, Uniper. “This is backed up by a near 20 percent automation of the remaining workload. This feeds directly into your business case (which is important) and provides welcome stability to my business units. I dream of such predictive maintenance in my generation fleet!”
Platform DXC and Agile Process Automation
Underpinning DXC Bionix is Platform DXC, the company’s digital-generation delivery platform that provides an important foundation for future services delivery — including applications, business process services, cloud, data analytics, security, and workplace and mobility solutions. Platform DXC allows DXC to quickly build and deliver partner-engineered, at-scale, repeatable offerings and solutions that help drive client digital transformations.
DXC’s recently announced Agile Process Automation (APA) is a new digital platform and a DXC Bionix enabled solution that combines cloud and robotic process automation (RPA) with embedded artificial intelligence (AI) to enhance a company’s business processes.
"Most end-user organizations don't have a line item in their budgets for digital transformation, so DXC Bionix is welcome news because it will help DXC identify where cash can be freed up from existing IT operations and reapplied to fund its clients' digital transformations," said Gard Little, vice president, Global Services Markets and Trends, IDC.
For more information on DXC Bionix, and to view a video featuring Steve Hilton, visit www.dxcbionix.com.
About DXC Technology
DXC Technology (NYSE: DXC) is the world’s leading independent, end-to-end IT services company, helping clients harness the power of innovation to thrive on change. Created by the merger of CSC and the Enterprise Services business of Hewlett Packard Enterprise, DXC Technology serves nearly 6,000 private and public sector clients across 70 countries. The company’s technology independence, global talent and extensive partner network combine to deliver powerful next-generation IT services and solutions. DXC Technology is recognized among the best corporate citizens globally. For more information, visit www.dxc.technology.
Richard Adamonis, Corporate Media Relations
Donna Jenks, Corporate Media Relations
Jonathan Ford, Investor Relations
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AURAK Gains SACSCOC Accreditation15.12.2018 10:49 | Pressemelding
The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now
Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41 | Pressemelding
Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42 | Pressemelding
Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00 | Pressemelding
Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07 | Pressemelding
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha